ActiveMSers Forums  

Go Back   ActiveMSers Forums > Forums > Dave's SCT Journey

Thread Tools Display Modes
Old 05-30-2017, 12:03 PM
ActiveMSers's Avatar
ActiveMSers ActiveMSers is offline
Dave @ ActiveMSers
Join Date: Jun 2008
Location: Albuquerque, NM
Posts: 3,292
Default CASE STUDY: After HSCT, highly active RRMS returned 2.5 years later

Highly active relapsing remitting multiple sclerosis following hematopoietic stem cell transplantation: a case report (P6.355)

Amanda Piquet, Laura Baldassari and M. Mateo Paz Soldan

Neurology April 18, 2017 vol. 88 no. 16 Supplement P6.355

Objective: We report the case of a 24-year-old woman with relapsing remitting multiple sclerosis (RRMS) resistant to several disease modifying therapies (DMT) who ultimately underwent non-myeloablative hematopoietic stem cell transplantation (HSCT). After 2.5 years free of relapses and off DMT, she developed highly active disease recurrence.

Background: HSCT has been investigated as a treatment for severe multiple sclerosis (MS) with failed response to standard immunotherapy. Non-myeloablative HSCT studies report a four year relapse-free survival of 80% and progression-free survival of 87%. Another phase II clinical trial using high-dose immunosuppressive therapy with autologous HSCT demonstrated relapse-free survival of 90.9% and progression-free survival of 86.3% at three years.

Design/Methods: Case report

Results: This patient with RRMS with ongoing clinical and MRI disease activity despite therapies with interferon beta-1a, fingolimod, dimethyl fumarate and methylprednisolone and allergic reaction to natalizumab underwent non-myeloablative HSCT. Afterwards she was relapse free for 2.5 years and remained off DMT, until she had a relapse during her 35th week of pregnancy characterized by sensory symptoms and a T6 spinal level. She was found to have more than 30 enhancing lesions in the brain and spinal cord.

Conclusions: HSCT has shown success in treating patients with MS refractory to standard immunotherapy; however, here we present a case of highly active RRMS only 2.5 years after transplantation in the setting of pregnancy. A phase II trial assessing the effect of HSCT on disease activity measured by MRI has reported a median number of 2.5 lesions over a four year period (range 08), while our patient had a significant lesion burden with > 30 lesions detected on MRI. There has been one prior case report of relapsing tumefactive MS 8 years post-HSCT. To our knowledge, no case of relapse during pregnancy following HSCT has been reported previously.
Dave Bexfield
Reply With Quote

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off
Forum Jump

All times are GMT -4. The time now is 10:14 AM.

Powered by vBulletin® Version 3.7.0
Copyright ©2000 - 2018, Jelsoft Enterprises Ltd.